ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Prospective Phase II Trial of Prognostication byJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- Path beyond the blind end-unravel the imaging spectrum of appendiceal pathologies.Abdominal radiology (New York) · 2026Review
- Article
- Unveiling the potential of copper-61 vs. gallium-68 for SSTR PET imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Current and Future Applications of PET Radiomics in Radiation Oncology.PET clinics · 2025Review
- Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.Journal of medicinal chemistry · 2025Review
- Models using comprehensive, lesion-level, longitudinal [European journal of nuclear medicine and molecular imaging · 2024Article
- Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.Experimental hematology & oncology · 2024Review
- Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.Diagnostics (Basel, Switzerland) · 2024Review
- PET/MRI imaging in neuroendocrine neoplasm.Abdominal radiology (New York) · 2023Review
- The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
- PET/CT and PET/MRI in neuroendocrine neoplasms.Abdominal radiology (New York) · 2022Review
- PET Oncological Radiopharmaceuticals: Current Status and Perspectives.Molecules (Basel, Switzerland) · 2022Review
- Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets.Pharmaceuticals (Basel, Switzerland) · 2022Article
- A convolutional neural network for total tumor segmentation in [EJNMMI research · 2022Article
- Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.World journal of gastroenterology · 2022Review
- Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [Cancers · 2022Review
- Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study.European journal of hybrid imaging · 2021Article
- Semiautomatic Tumor Delineation for Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Initial Experience withDiagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of somatostatin receptors (SSTRs) in patients with neuroendocrine neoplasms (NENs) is used for both diagnosis and treatment. Receptor density may reflect tumor differentiation and thus be associated with prognosis. Noninvasive visualization and quantification of SSTR density is possible by SSTR imaging (SRI) using PET. Recently, we introduced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.